Advanced search
Publication Cover
Annals of Medicine Volume 56, 2024 - Issue 1
Submit an article Journal homepage
650
Views
0
CrossRef citations to date
0
Altmetric
Public Health

Efficacy of the COVID-19 vaccination in patients with asymptomatic or mild illness during the Omicron epidemic in Guangzhou: a multi-centre retrospective cohort study

Yuanda Xua State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. ChinaORCID Iconhttps://orcid.org/0000-0002-7843-8876View further author information
ORCID Icon,
Xuetao Konga State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. China;b Department of Public Health, Guangzhou Medical University, Guangzhou, ChinaORCID Iconhttps://orcid.org/0000-0001-7586-1559View further author information
ORCID Icon,
Weiqing Huanga State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. ChinaView further author information
,
Zijing Lianga State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. ChinaView further author information
,
Jinkun Huanga State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. ChinaView further author information
,
Yimin Lia State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. ChinaView further author information
,
Nuofu Zhanga State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. ChinaView further author information
,
Dan Liua State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. ChinaView further author information
,
Wenwei Guoa State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. ChinaView further author information
&
Jiang Meia State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Critical Care Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. ChinaCorrespondence[email protected]
View further author information
 show all
Article: 2307504 | Received 13 Aug 2023, Accepted 15 Jan 2024, Published online: 11 Mar 2024

References

  • WHO; 2023 [cited 2023 Jul 5]. Available from: https://www.who.int/data#dashboards
  • Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):1–11. doi: 10.1038/s41562-021-01122-8.
  • Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–891. doi: 10.1016/S0140-6736(21)00432-3.
  • Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi: 10.1056/NEJMoa2035389.
  • Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45. doi: 10.1001/jama.2021.8565.
  • Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397(10286):1725–1735. doi: 10.1016/S0140-6736(21)00790-X.
  • Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. doi: 10.1038/s41591-021-01377-8.
  • Krause PR, Fleming TR, Peto R, et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021;398(10308):1377–1380. doi: 10.1016/S0140-6736(21)02046-8.
  • Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 variants and vaccines. N Engl J Med. 2021;385(2):179–186. doi: 10.1056/NEJMsr2105280.
  • Zhang Y, Lv Q, Qi F, et al. Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro. Anim Mod Exp Med. 2023;6(1):51–56. doi: 10.1002/ame2.12302.
  • Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi: 10.1038/s41586-020-2012-7.
  • Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184(9):2384–2393.e12. doi: 10.1016/j.cell.2021.03.036.
  • World Health Organization. Interim recommendations for heterologous COVID-19 vaccine schedules: interim guidance. Geneva: World Health Organization; 2021.
  • Alhinai Z, Park S, Choe YJ, et al. A global epidemiological analysis of COVID-19 vaccine types and clinical outcomes. Int J Infect Dis. 2022;124:206–211. doi: 10.1016/j.ijid.2022.09.014.
  • Colavita F, Meschi S, Gruber CEM, et al. Virological and serological characterisation of SARS-CoV-2 infections diagnosed after mRNA BNT162b2 vaccination between December 2020 and March 2021. Front Med. 2021;8:815870. doi: 10.3389/fmed.2021.815870.
  • Humphrey L, Thommes EW, Fields R, et al. Large-scale frequent testing and tracing to supplement control of covid-19 and vaccination rollout constrained by supply. Infect Dis Model. 2021;6:955–974. doi: 10.1016/j.idm.2021.06.008.
  • Laine C, Cotton D, Moyer DV. COVID-19 vaccine: promoting vaccine acceptance. Ann Intern Med. 2021;174(2):252–253. doi: 10.7326/M20-8008.
  • Yang ZR, Jiang YW, Li FX, et al. Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. Lancet Microbe. 2023;4(4):e236–e246. doi: 10.1016/S2666-5247(22)00390-1.
  • Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl. 1):S31–S34. doi: 10.4103/sja.SJA_543_18.
  • Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using National Surveillance Data. Lancet. 2021;397(10287):1819–1829. doi: 10.1016/S0140-6736(21)00947-8.
  • Yang D, Weng H, Wang R, et al. Evaluation of COVID-19 vaccines in primary prevention against infections and reduction in severity of illness following the outbreak of SARS-CoV-2 Omicron variant in Shanghai. Front Med. 2023;10:1079165. doi: 10.3389/fmed.2023.1079165.
  • Vitiello A, Ferrara F, Troiano V, et al. COVID-19 vaccines and decreased transmission of SARS-CoV-2. Inflammopharmacology. 2021;29(5):1357–1360. doi: 10.1007/s10787-021-00847-2.
  • Li T, Luo KQ. Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. Int J Biol Sci. 2022;18(12):4642–4647. doi: 10.7150/ijbs.72424.
  • Tsang NNY, So HC, Cowling BJ, et al. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 Omicron BA.2 in Hong Kong: a prospective cohort study. Lancet Infect Dis. 2023;23(4):421–434. doi: 10.1016/S1473-3099(22)00732-0.
  • Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303–1312. doi: 10.1016/S0140-6736(22)00462-7.
  • Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N Engl J Med. 2021;384(23):2187–2201. doi: 10.1056/NEJMoa2101544.
  • Zeng B, Gao L, Zhou Q, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20(1):200. doi: 10.1186/s12916-022-02397-y.
  • Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022;399(10321):237–248. doi: 10.1016/S0140-6736(21)02753-7.
  • Bello-Chavolla OY, Antonio-Villa NE, Valdés-Ferrer SI, et al. Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of National Surveillance Data. Int J Infect Dis. 2023;129:188–196. doi: 10.1016/j.ijid.2023.01.040.
  • Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–944. doi: 10.1016/S0140-6736(22)00152-0.
  • Kampf G, Lemmen S, Suchomel M. Ct values and infectivity of SARS-CoV-2 on surfaces. Lancet Infect Dis. 2021;21(6):e141. doi: 10.1016/S1473-3099(20)30883-5.
  • Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021;595(7865):17–18. doi: 10.1038/d41586-021-01696-3.
  • Thompson MG, Burgess JL, Naleway AL, et al. Prevention and attenuation of covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320–329. doi: 10.1056/NEJMoa2107058.
  • Levine-Tiefenbrun M, Yelin I, Katz R, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27(5):790–792. doi: 10.1038/s41591-021-01316-7.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.